The DOI matches its Crossref record; 16 of the 16 references it cites were found in a registry or an index.
Systematic review: the efficacy of treatments for irritable bowel syndrome – a European perspective
Open accessAbstract
Summary: Background: Irritable bowel syndrome (IBS) is a common, chronic disorder, characterized by abdominal pain/discomfort, bloating and altered bowel habit. Aim: To conduct a systematic evidence‐based review of pharmacological therapies currently used, or in clinical development, for the treatment of IBS in Europe. The safety and tolerability of these therapies are the subject of an accompanying review. Methods: A literature search was completed for randomized controlled studies which included adult patients with IBS and an active or placebo control, assessed IBS symptoms, and were published in English between January 1980 and June 2005. The level of evidence for efficacy was graded according to the quality of the trial design and the study outcome. Results: There is some evidence for improvement of individual IBS symptoms with antidiarrhoeals (diarrhoea), antispasmodics (abdominal pain/discomfort), bulking agents (constipation), tricyclic antidepressants (abdominal pain/discomfort) and behavioural therapy. In contrast, there is strong evidence for the improvement of global IBS symptoms with two new serotonergic agents: the 5‐HT 4 selective agonist tegaserod (IBS with constipation) and the 5‐HT 3 antagonist alosetron (IBS with diarrhoea). Further data are required for the 5‐HT 3 antagonist, cilansetron, and the mixed 5‐HT 3 antagonist/5‐HT 4 agonist renzapride before their utility in IBS can be appraised. Conclusions: There is limited evidence for the efficacy, safety and tolerability of therapies currently available in Europe for the treatment of IBS. Overall, there is an absence of pharmacological agents licensed specifically for the treatment of IBS subtypes, and new agents are awaited in Europe that will allow changes in clinical practice to focus on and improve global IBS symptoms.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Functional bowel disorders and functional abdominal pain
Thompson, W. G., Longstreth, G. F., Drossman, D. A., Heaton, K. W., Irvine, E. J., & Müller-Lissner, S. A. (1999) · Gut · doi:10.1136/gut.45.2008.ii43 · Cited by 2,440
Whitehead, W. E., Palsson, O., & Jones, K. R. (2002) · Gastroenterology · doi:10.1053/gast.2002.32392 · Cited by 1,116
Design of Treatment Trials for Functional Gastrointestinal Disorders
Irvine, E. J., Tack, J., Crowell, M. D., Gwee, K. A., Ke, M., Schmulson, M. J., Whitehead, W. E., & Spiegel, B. (2016) · Gastroenterology · doi:10.1053/j.gastro.2016.02.010 · Cited by 550
Self-citationCONTROLLED TRIAL OF HYPNOTHERAPY IN THE TREATMENT OF SEVERE REFRACTORY IRRITABLE-BOWEL SYNDROME
Whorwell, P. J., Prior, A., & Faragher, E. B. (1984) · The Lancet · doi:10.1016/s0140-6736(84)92793-4 · Cited by 537
Niedzielin, K., Kordecki, H., & Birkenfeld, B. (2001) · European Journal of Gastroenterology & Hepatology · doi:10.1097/00042737-200110000-00004 · Cited by 506
The cost-effectiveness of psychotherapy and paroxetine for severe irritable bowel syndrome
Creed, F., Fernandes, L., Guthrie, E., Palmer, S., Ratcliffe, J., Read, N., Rigby, C., Thompson, D., & Tomenson, B. (2003) · Gastroenterology · doi:10.1053/gast.2003.50055 · Cited by 443
Effect of alosetron on responses to colonic distension in patients with irritable bowel syndrome
Delvaux, M., Louvel, D., Mamet, J. ‐., Campos‐Oriola, R., & Frexinos, J. (1998) · Alimentary Pharmacology & Therapeutics · doi:10.1046/j.1365-2036.1998.00375.x · Cited by 236
Payne, A., & Blanchard, E. B. (1995) · Journal of Consulting and Clinical Psychology · doi:10.1037/0022-006x.63.5.779 · Cited by 186
Boyce, P. M., Talley, N. J., Balaam, B., Koloski, N. A., & Truman, G. (2003) · American Journal of Gastroenterology · doi:10.1111/j.1572-0241.2003.07716.x · Cited by 167
Individual and group hypnotherapy in treatment of refractory irritable bowel syndrome
Harvey, R. F., Gunary, R. M., Hinton, R. A., & Barry, R. E. (1989) · The Lancet · doi:10.1016/s0140-6736(89)90013-5 · Cited by 161
Research works printed but not linked: 131
- 10.1046/j.1365-2036.2003.01456.x · DOI · Paper page
- 10.1001/archinte.163.8.929 · DOI · Paper page
- Zacker C, 2004, Absenteeism among employees with irritable bowel syndrome, Manag Care Interface, 17, 28
- Smith GD, 2004, A comparison of irritable bowel syndrome patients managed in primary and secondary care: the Episode IBS study, Br J Gen Pract, 54, 503
- 10.2165/00019053-200220070-00003 · DOI · Paper page
- Brandt LJ, 2002, Systematic review on the management of irritable bowel syndrome in North America, Am J Gastroenterol, 97, S7, 10.1016/S0002-9270(02)05657-5 · DOI · Paper page
- 10.1055/s-2002-22324 · DOI
- Kong SC, 2005, The incidence of self‐prescribed oral complementary and alternative medicine use by patients with gastrointestinal diseases, J Clin Gastroenterol, 39, 138
- 10.1097/00042737-200212000-00007 · DOI
- 10.1097/00042737-200410000-00008 · DOI
- 10.1002/pds.997 · DOI
- ACG, 2002, American College of Gastroenterology Functional Gastrointestinal Disorders Task Force. Evidence‐based position statement on the management of irritable bowel syndrome in North America, Am J Gastroenterol, 97, S1, 10.1016/S0002-9270(02)05656-3 · DOI
- CPMP, 2003, Points to Consider on the Evaluation of Medicinal Products for the Treatment of Irritable Bowel Syndrome
- Wheatley D, 1976, Irritable colon syndrome treated with an anti‐spasmodic drug, Practitioner, 217, 276
- 10.1097/00004836-198106000-00009 · DOI
- 10.1136/bmj.1.6160.376 · DOI
- 10.1159/000199329 · DOI
- Tudor GJ, 1986, A general practice study to compare alverine citrate with mebeverine hydrochloride in the treatment of irritable bowel syndrome, Br J Clin Pract, 40, 276, 10.1111/j.1742-1241.1986.tb07977.x · DOI
- Chapman ND, 1990, A comparison of mebeverine with high‐fibre dietary advice and mebeverine plus ispaghula in the treatment of irritable bowel syndrome: an open, prospectively randomized, parallel group study, Br J Clin Pract, 44, 461, 10.1111/j.1742-1241.1990.tb10058.x · DOI
- Awad R, 1995, Irritable bowel syndrome treatment using pinaverium bromide as a calcium channel blocker. A randomized double‐blind placebo‐controlled trial, Acta Gastroenterol Latinoam, 25, 137
- Baldi F, 1991, Clinical and functional evaluation of the efficacy of otilonium bromide: a multicenter study in Italy, Ital J Gastroenterol Hepatol, 23, 60
- Villagrasa M, 1991, Aleatory clinical study comparing otilonium bromide with a fiber‐rich diet in the treatment of irritable bowel syndrome, Ital J Gastroenterol, 23, 67
- 10.1046/j.1365-2036.1998.00397.x · DOI
- 10.1097/00042737-200212000-00008 · DOI
- Ferrari A, 1986, Double‐blind study of a new antimuscarinic, cimetropium bromide, in patients with irritable bowel syndrome, Clin Ther, 8, 320
- Piai G, 1987, Long‐term treatment of irritable bowel syndrome with cimetropium bromide, a new antimuscarinic compound, Curr Ther Res, 41, 967
- Centonze V, 1988, Oral cimetropium bromide, a new antimuscarinic drug, for long‐term treatment of irritable bowel syndrome, Am J Gastroenterol, 83, 1262
- 10.1136/gut.31.3.355 · DOI
- Fielding JF, 1980, Double blind trial of trimebutine in the irritable bowel syndrome, Ir Med J, 73, 377
- 10.1185/03007998009109464 · DOI
- Ghidini O, 1986, Single drug treatment for irritable colon: rociverine versus trimebutine maleate, Curr Ther Res, 39, 541
- Schaffstein W, 1990, Comparative safety and efficacy of trimebutine versus mebeverine in the treatment of irritable bowel syndrome, Curr Ther Res, 47, 136
- 10.1007/BF02943704 · DOI
- Piai G, 1986, Treatment of irritable bowel syndrome, Clin Trials J, 23, 6
- 10.1016/S0210-5705(03)70470-1 · DOI
- Quartero A, 2005, Bulking agents, antispasmodic and antidepressant medication for the treatment of irritable bowel syndrome, Cochrane Database Syst Rev, CD003460
- 10.1111/j.1365-2036.2004.02267.x · DOI · Paper page
- 10.1111/j.1365-2036.1994.tb00322.x · DOI · Paper page
- 10.1016/S0140-6736(76)91402-1 · DOI
- 10.1016/S0140-6736(77)90605-5 · DOI
- 10.7326/0003-4819-95-1-53 · DOI
- Golechha AC, 1982, Role of ispaghula husk in the management of irritable bowel syndrome (a randomized double‐blind crossover study), J Assoc Physicians India, 30, 353
- Arthurs Y, 1983, Double blind trial of ispaghula/poloxamer in the Irritable Bowel Syndrome, Ir Med J, 76, 253
- 10.3109/00365528509091653 · DOI
- 10.1136/gut.28.2.221 · DOI
- 10.1136/gut.28.11.1510 · DOI
- 10.1016/0016-5085(90)91292-E · DOI
- 10.1111/j.1440-1746.1990.tb01432.x · DOI
- 10.1111/j.1365-2036.1993.tb00074.x · DOI
- 10.1111/j.1365-2036.1994.tb00323.x · DOI
- 10.1016/0022-3999(92)90026-X · DOI
- 10.1159/000198701 · DOI
- 10.1016/j.nut.2004.05.016 · DOI
- 10.1177/146642400512500112 · DOI
- 10.1007/BF01296258 · DOI · Paper page
- 10.3109/00365528709091004 · DOI
- 10.3109/00365529609006766 · DOI · Paper page
- 10.3109/00365528709091003 · DOI · Paper page
- 10.1023/B:APBI.0000017861.60439.95 · DOI
- Halpern GM, 1996, Treatment of irritable bowel syndrome with Lacteol Fort: a randomized, double‐blind, cross‐over trial, Am J Gastroenterol, 91, 1579
- 10.1136/gut.24.12.1135 · DOI
- 10.1185/03007998009109491 · DOI
- 10.1016/S0033-3182(78)70930-8 · DOI
- 10.2190/WFHG-GR7T-79D6-UQVD · DOI
- 10.3109/00365528209181108 · DOI
- 10.1080/00365521.1984.12005817 · DOI
- 10.1007/BF01297051 · DOI · Paper page
- Vij JG, 1991, Effect of antidepressant drug (doxepin) on irritable bowel syndrome, Indian J Psychiatry, 33, 243
- 10.1111/j.1440-1746.1998.tb00723.x · DOI
- 10.1111/j.1572-0241.2004.04127.x · DOI · Paper page
- 10.1016/S1542-3565(03)70039-1 · DOI · Paper page
- 10.1016/S0016-5085(00)80649-6 · doi:10.1016/s0016-5085(00)80649-6
- 10.1046/j.1365-2036.2001.01094.x · DOI · Paper page
- 10.1046/j.1365-2036.2002.01372.x · DOI · Paper page
- 10.1136/gut.52.5.671 · DOI · Paper page
- Hämling J, 1998, Titration regimen indicates partial 5‐HT4 agonist HTF 919 improves symptoms of constipation predominant irritable bowel syndrome (C‐IBS), Digestion, 59, 735
- Lefkowitz MP, 1999, The 5‐HT4 partial agonist, tegaserod, improves abdominal discomfort/pain and normalizes altered bowel function in irritable bowel syndrome (IBS), Am J Gastroenterol, 94, 266
- Lefkowitz MP, 1999, Relief of overall GI symptoms and abdominal pain and discomfort as outcome measures in a clinical trial of irritable bowel syndrome with HTF 919, Gastroenterology, 116, A1027
- 10.1080/00365520310006748 · DOI
- Tack J, 2004, Tegaserod provides rapid and sustained relief of overall IBS symptoms and abdominal discomfort/pain when used as repeated treatment in women with IBS‐C, Gut, 53, A69
- 10.1111/j.1572-0241.2002.05692.x · DOI
- Schoenfeld P, 2002, Effectiveness and safety of tegaserod in the treatment of irritable bowel syndrome: a meta‐analysis of randomized controlled trials, Gastroenterology, 122, A46S
- 10.1053/gast.2001.21166 · DOI · Paper page
- 10.1159/000070202 · DOI
- 10.1517/14656566.4.11.2089 · DOI
- 10.1046/j.1365-2036.1996.30172000.x · DOI
- 10.1159/000201377 · DOI
- 10.1016/S0025-6196(12)60797-6 · DOI
- 10.1046/j.1365-2036.1999.00610.x · DOI · Paper page
- 10.1046/j.1365-2036.1999.00678.x · DOI
- 10.1016/S0140-6736(00)02033-X · DOI · Paper page
- 10.1111/j.1572-0241.2001.04128.x · doi:10.1111/j.1572-0241.2001.04128.x · Paper page
- 10.1046/j.1365-2036.2000.00684.x · DOI · Paper page
- 10.1001/archinte.161.14.1733 · DOI · Paper page
- 10.1111/j.1572-0241.2004.30509.x · DOI
- 10.1016/S1542-3565(04)00284-8 · DOI
- 10.1046/j.1365-2982.2003.00389.x · DOI · Paper page
- Bradette M, 2004, Cilansetron in irritable bowel syndrome with diarrhoea predominance (IBS‐D): efficacy and safety in a 6 month global study, Gastroenterology, 126, A42
- Coremans G, 2004, Cilansetron, a novel 5‐HT3 antagonist demonstrated efficacy in males with irritable bowel syndrome with diarrhoea‐predominance (IBS‐D), Gastroenterology, 126, A‐643
- 10.1097/00004836-199102000-00012 · DOI
- 10.1046/j.1365-2036.1997.133311000.x · DOI
- 10.1080/00365529850166833 · DOI
- 10.1080/00365529850171873 · DOI
- 10.1111/j.1440-1746.2004.03384.x · DOI
- Henderson JC, 2004, A phase IIb clinical study of renzapride in mixed‐symptom (alternating) irritable bowel syndrome, Gastroenterology, 126, A‐915
- Meyers N, 2004, Efficacy and safety of renzapride in patients with constipation‐predominant IBS: a Phase IIb study in the UK primary healthcare setting, Gastroenterology, 126, A‐640
- 10.1016/S1542-3565(04)00391-X · DOI
- 10.2165/00002018-200427040-00002 · DOI
- 10.1177/107424840200700202 · DOI
- 10.1016/S0140-6736(83)90678-5 · DOI · Paper page
- 10.1111/j.2044-8260.1985.tb01340.x · DOI
- 10.1016/S0005-7894(89)80130-3 · DOI
- 10.1016/0022-3999(91)90041-L · DOI
- Rumsey N, 1991, Towards Confident Management of Irritable Bowel Syndrome: Current Approaches, 33
- 10.1159/000200738 · DOI
- 10.1016/0005-7967(92)90141-3 · DOI
- 10.1007/BF00999789 · DOI
- 10.1192/bjp.163.3.315 · DOI
- 10.1037/0022-006X.62.3.576 · DOI · Paper page
- 10.1111/j.1572-0241.2000.01937.x · DOI · Paper page
- 10.1016/S0005-7894(98)80016-6 · DOI · Paper page
- 10.1097/01.psy.0000116964.76529.6e · DOI · Paper page
- 10.1007/s003840000248 · DOI
- 10.1046/j.1365-2036.2002.01320.x · DOI
- 10.1007/BF02209014 · DOI
- 10.1053/cgh.2003.50019 · DOI
- Pimentel M, 2003, Normalization of lactulose breath testing correlates with symptom improvement in irritable bowel syndrome. a double‐blind, randomized, placebo‐controlled study, Am J Gastroenterol, 98, 412
- 10.1007/BF02936952 · DOI · Paper page
- 10.1001/jama.280.18.1585 · DOI · Paper page
- 10.1111/j.1365-2036.2005.02330.x · DOI
- 10.1097/01.mcg.0000139029.00451.c7 · DOI
Cited by
Enck, P., Aziz, Q., Barbara, G., Farmer, A. D., Fukudo, S., Mayer, E. A., Niesler, B., Quigley, E. M. M., Rajilić-Stojanović, M., Schemann, M., et al. (2016) · Nature Reviews Disease Primers · doi:10.1038/nrdp.2016.14 · Cited by 997
Ford, A. C., Talley, N. J., Schoenfeld, P. S., Quigley, E. M. M., & Moayyedi, P. (2009) · Gut · doi:10.1136/gut.2008.163162 · Cited by 582
Ford, A. C., Talley, N. J., Spiegel, B. M. R., Foxx-Orenstein, A. E., Schiller, L., Quigley, E. M. M., & Moayyedi, P. (2008) · BMJ · doi:10.1136/bmj.a2313 · Cited by 565
American College of Gastroenterology Monograph on Management of Irritable Bowel Syndrome
Ford, A. C., Moayyedi, P., Chey, W. D., Harris, L. A., Lacy, B. E., Saito, Y. A., & Quigley, E. M. M. (2018) · American Journal of Gastroenterology · doi:10.1038/s41395-018-0084-x · Cited by 388
Bulking agents, antispasmodics and antidepressants for the treatment of irritable bowel syndrome
Ruepert, L., Quartero, A. O., de Wit, N. J., van der Heijden, G. J., Rubin, G., & Muris, J. W. (2011) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd003460.pub3 · Cited by 389
Metadata
- Authors
- TACK, J., FRIED, M., HOUGHTON, L. A., SPICAK, J., & FISHER, G.
- Venue
- Alimentary Pharmacology & Therapeutics
- Publisher
- Wiley
- Published
- 2006-06-26
- Volume
- 24
- Issue
- 2
- Pages
- 183-205
- ISSN
- 0269-2813 (ISSN-L)
- 1365-2036
- OpenAlex
- W2060809912
- Cited by
- 169
- References
- 16
- FWCI
- 2.06
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Systematic review: the efficacy of treatments for irritable bowel syndrome – a European perspective. https://app.cochat.ai/papers/10.1111/j.1365-2036.2006.02938.x
- The paper
- TACK, J., FRIED, M., HOUGHTON, L. A., SPICAK, J., & FISHER, G. (2006). Systematic review: the efficacy of treatments for irritable bowel syndrome – a European perspective. Alimentary Pharmacology & Therapeutics. https://doi.org/10.1111/j.1365-2036.2006.02938.x
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.